CeriBell, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
CeriBell, Inc. (CBLL) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-10
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 4.00%, a 2.56% increase year-over-year.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.80%, a 15.56% decline year-over-year.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 3.90%, a 15.22% decline year-over-year.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.50%, a 12.50% increase year-over-year.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.90%, a 4.88% decline from fiscal 2024.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.10%, a 2.38% decline from fiscal 2023.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.20%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.00% 10-Q · filed 2026-08-10 | 4.00% 10-Q · filed 2026-08-10 | ||
| 2026-03-31 | 3.80% 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 3.90% 10-K · filed 2026-02-24 | |||
| 2025-09-30 | 3.90% 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 3.90% 10-Q · filed 2026-08-10 | 3.90% 10-Q · filed 2026-08-10 | ||
| 2025-03-31 | 4.50% 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | 4.10% 10-K · filed 2026-02-24 | |||
| 2024-09-30 | 3.80% 10-Q · filed 2025-11-04 | 4.10% 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | 4.60% 10-Q · filed 2025-08-05 | 4.50% 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | 4.00% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 4.20% 10-K · filed 2025-02-25 | |||
| 2023-09-30 | 4.50% 10-Q · filed 2024-11-12 | 4.10% 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |